Improving the treatment of Parkinson´s disease
| Reference number | |
| Coordinator | Lunds universitet - Institutionen för experimentell medicinsk vetenskap, Lund |
| Funding from Vinnova | SEK 2 900 000 |
| Project duration | July 2019 - June 2021 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Swelife and Medtech4Health - Collaborative Projects for Improved Health (Spring 2019) |
Purpose and goal
The main purpose of this project was to deepen the mechanistic understanding and to strengthen the overall documentation of the novel compound Mesdopetam (IRL790), for the treatment of levodopa-induced dyskinesia and Parkinson psychosis with the aim of securing commercialization that will lead to the further development towards an approved drug.
Expected results and effects
By improving the symptomatic treatment of Parkinson’s disease (PD), we will increase the quality of life for many of the approximately 20 000 PD patients in Sweden that live with this chronic disease. In particular, we aim to develop a new therapy to treat motor complications and psychosis affecting the majority of late-stage PD patients.
Planned approach and implementation
The new substance Mesdopetam (IRL790), has been directly tested against the only two approved drugs for treatment of levodopa-induced dyskinesia and Parkinson psychosis, respectively, in validated animal models of the disease. We have investigated to what extent the different treatments can alleviate symptoms and how activity patterns in the brain change in association with the treatment. These data will help build a better understanding of the treatment mechanisms for the new compound information that is of key importance in the further development towards and approved drug.